These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 33615756)

  • 21. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
    Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal toxicities associated with immune checkpoint inhibitors: a disproportionality analysis leveraging VigiBase, the WHO Adverse Drug Reaction Database.
    Huang S; Bai X; Fang T; Guo Y; Zheng K; Lin X
    J Zhejiang Univ Sci B; 2021 Feb; 22(2):156-164. PubMed ID: 33615756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019.
    Hu F; Ye X; Zhai Y; Xu J; Guo X; Guo Z; Zhou X; Ruan Y; Zhuang Y; He J
    Immunotherapy; 2020 May; 12(7):531-540. PubMed ID: 32456497
    [No Abstract]   [Full Text] [Related]  

  • 24. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
    Reese SW; Cone E; Marchese M; Garcia B; Chou W; Ayub A; Kilbridge K; Weinhouse G; Trinh QD
    Lung; 2021 Apr; 199(2):199-211. PubMed ID: 33616727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Chen C; Wu B; Zhang C; Xu T
    Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
    Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
    Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
    Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal involvement of COVID-19 and potential faecal transmission of SARS-CoV-2.
    Song M; Li ZL; Zhou YJ; Tian G; Ye T; Zeng ZR; Deng J; Wan H; Li Q; Liu JB
    J Zhejiang Univ Sci B; 2020 Sept.; 21(9):749-751. PubMed ID: 32893532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microencapsulation of immunoglobulin Y: optimization with response surface morphology and controlled release during simulated gastrointestinal digestion.
    Zhang J; Li HH; Chen YF; Chen LH; Tang HG; Kong FB; Yao YX; Liu XM; Lan Q; Yu XF
    J Zhejiang Univ Sci B; 2020 Aug.; 21(8):611-627. PubMed ID: 32748577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal Tract Adverse Events.
    Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytomegalovirus ileo-pancolitis presenting as toxic megacolon in an immunocompetent patient: A case report.
    Cho JH; Choi JH
    World J Clin Cases; 2020 Feb; 8(3):552-559. PubMed ID: 32110666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
    Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
    J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines.
    Yuan Z; Yang H; Wei Y
    Int J Clin Exp Pathol; 2019; 12(1):123-132. PubMed ID: 31933726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Checkpoint Inhibitors in Lung Cancer and Melanoma.
    Madden K; Kasler MK
    Semin Oncol Nurs; 2019 Oct; 35(5):150932. PubMed ID: 31561846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies.
    Zhang ML; Neyaz A; Patil D; Chen J; Dougan M; Deshpande V
    Histopathology; 2020 Jan; 76(2):233-243. PubMed ID: 31361907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
    Gu L; Khadaroo PA; Su H; Kong L; Chen L; Wang X; Li X; Zhu H; Zhong X; Pan J; Chen M
    BMC Cancer; 2019 Jun; 19(1):559. PubMed ID: 31182049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
    Doroshow DB; Sanmamed MF; Hastings K; Politi K; Rimm DL; Chen L; Melero I; Schalper KA; Herbst RS
    Clin Cancer Res; 2019 Aug; 25(15):4592-4602. PubMed ID: 30824587
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.